Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (VRTX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
vrtx · stock forecast · 56 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 56 Wall Street analysts in the past 3 months
Buy
56 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$616
Consensus
$554
+24.0% upside
Low
$436
Median: $558 · Last Close: $446.83
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$553.93
24.0% upside
High Target
$616
37.9%
Low Target
$436
-2.4%
Current Price
$446.83
as of today
Based on analyst price targets, the VRTX stock price prediction for the next 12 months ranges from $436 to $616. The consensus VRTX price forecast of $553.93 implies 24.0% upside from the current price of $446.83.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $444.64 | ↓ 0.49% |
1-day model range: $443.42–$445.87. Peak: $445.87 (-0.49%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $574 | +28.4% |
| 2028 | $680 | +52.1% |
| 2029 | $761 | +70.3% |
| 2030 | $820 | +83.6% |
| 2031 | — | +92.9% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · VRTX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-06 | Barclays | Maintains | Overweight→Overweight |
| 2026-05-05 | Canaccord Genuity | Maintains | Hold→Hold |
| 2026-05-05 | RBC Capital | Maintains | Outperform→Outperform |
| 2026-05-05 | Bernstein | Maintains | Outperform→Outperform |
| 2026-05-05 | Morgan Stanley | Maintains | Overweight→Overweight |
| 2026-04-30 | Canaccord Genuity | Maintains | Hold→Hold |
| 2026-04-10 | Morgan Stanley | Maintains | Overweight→Overweight |
| 2026-03-18 | Maxim Group | Upgrade ↑ | Hold→Buy |
| 2026-03-11 | Truist Securities | Maintains | Buy→Buy |
| 2026-03-10 | Morgan Stanley | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Vertex Pharmaceuticals Incorporated (VRTX) stock. Of the recent 562 rating actions, 50 were upgrades and 39 were downgrades. 56 analysts currently cover VRTX.
Analyst Recommendation Trends
VRTX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 4 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$13.0B
↓ 17.6% YoY
Revenue Next Year
$14.3B
↑ 9.5% YoY
EPS This Year
$19.31
EPS Next Year
$21.62
↑ 12.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast VRTX EPS of $19.31 for the current fiscal year, based on estimates from 19 analysts. The VRTX revenue forecast is $13.0B for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The VRTX stock forecast is supported by two independent data sources: analyst consensus ratings from 56 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus VRTX price target is $553.93 (+24.0% upside), with an analyst consensus of Buy.
The VRTX short-term stock prediction for tomorrow is $444.64 (-0.49%). The VRTX stock price prediction for 2027 estimates an average of $574. The VRTX stock prediction for 2030 projects a range of $796–$845.
Vertex Pharmaceuticals Incorporated trades on NASDAQ under the ticker VRTX. The VRTX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 84% of covering analysts.
Frequently asked questions
VRTX forecast · 8 questionsAccording to 56 Wall Street analysts, the average 12-month VRTX price target is $553.93, with a high forecast of $616.00 and a low of $436.00. The median price target is shown in the chart above when available. This implies +24.0% potential upside from the current price of $446.83.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.